Cadila Gets FDA Nod for Arthritis Drug (India)
This article was originally published in PharmAsia News
Major Indian pharmaceutical manufacturer Zydus Cadila Healthcare announced on Sept. 25 that it has received approval from the U.S. FDA for a new drug to treat rheumatoid arthritis. The FDA approval is for a 200mg dose of hydrochloroquine sulfate. The drug is one of a class of arthritis-fighting treatments known as disease modifying anti-rheumatic drugs (DMARD). DMARDs are designed to reduce the pain, inflammation, and joint damage caused by the disease for a period of several weeks or several months depending on the treatment. (Click here for more
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.